Baxter (BAX) Tops Q1 EPS by 11c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Baxter Reports First-Quarter 2021 Results
April 29, 2021 7:15 AM EDTFirst-quarter revenue of $2.9 billion increased 5% on a reported basis and 1% on both a constant currency and operational basis1 First-quarter U.S. GAAP earnings per share (EPS) of $0.58 declined 9%; Adjusted EPS of $0.76 declined 7% Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis Baxter expects full-year U.S. GAAP EPS of $2.85 to $2.93 and adjusted EPS of $3.47 to $3.55
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX), a leading global medical products... More
